{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T07:23:14Z","timestamp":1787642594238,"version":"build-2736575974"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","award":["AWD00008424"],"award-info":[{"award-number":["AWD00008424"]}],"id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","award":["AWD00008424"],"award-info":[{"award-number":["AWD00008424"]}],"id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The study was supported in part by the Steve and Nancy Fox Research Funds and various donor research funds provided to Michael Wang by MD Anderson Cancer Center."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41375-026-03032-y","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T12:51:17Z","timestamp":1783601477000},"page":"2048-2052","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reversible and irreversible BTK inhibition promotes stem-like functional multipotency, persistence, and antitumor efficacy of CD19-directed CAR T cells in mantle cell lymphoma"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8439-6043","authenticated-orcid":false,"given":"Yixin","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6231-5225","authenticated-orcid":false,"given":"Fangfang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"McIntosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1910-8076","authenticated-orcid":false,"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-5486","authenticated-orcid":false,"given":"Michael","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"3032_CR1","doi-asserted-by":"publisher","first-page":"4122","DOI":"10.1182\/bloodadvances.2022007247","volume":"6","author":"M Narkhede","year":"2022","unstructured":"Narkhede M, Goyal G, Shea L, Mehta A, Giri S. Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma. Blood Adv. 2022;6:4122\u201331.","journal-title":"Blood Adv"},{"key":"3032_CR2","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1182\/blood.2023021306","volume":"143","author":"A Minson","year":"2024","unstructured":"Minson A, Hamad N, Cheah CY, Tam C, Blombery P, Westerman D, et al. CAR T cells and time-limited ibrutinib as treatment for relapsed\/refractory mantle cell lymphoma: the phase 2 TARMAC study. Blood. 2024;143:673\u201384.","journal-title":"Blood"},{"key":"3032_CR3","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-15-1527","volume":"22","author":"M Ruella","year":"2016","unstructured":"Ruella M, Kenderian SS, Shestova O, Fraietta JA, Qayyum S, Zhang Q, et al. The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. Clin Cancer Res. 2016;22:2684\u201396.","journal-title":"Clin Cancer Res"},{"key":"3032_CR4","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s11912-022-01286-0","volume":"24","author":"JL Munoz","year":"2022","unstructured":"Munoz JL, Wang Y, Jain P, Wang M. BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma-Finding a Dancing Partner. Curr Oncol Rep. 2022;24:1299\u2013311.","journal-title":"Curr Oncol Rep"},{"key":"3032_CR5","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1111\/cas.14915","volume":"112","author":"M Liu","year":"2021","unstructured":"Liu M, Deng H, Mu J, Li Q, Pu Y, Jiang Y, et al. Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma. Cancer Sci. 2021;112:2642\u201351.","journal-title":"Cancer Sci"},{"key":"3032_CR6","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/blood-2023-183029","volume":"142","author":"EB Gomez","year":"2023","unstructured":"Gomez EB, Ebata K, Randeria HS, Rosendahl MS, Cedervall EP, Morales TH, et al. Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor. Blood. 2023;142:62\u201372.","journal-title":"Blood"},{"key":"3032_CR7","doi-asserted-by":"publisher","first-page":"3988","DOI":"10.1200\/JCO.23.00562","volume":"41","author":"ML Wang","year":"2023","unstructured":"Wang ML, Jurczak W, Zinzani PL, Eyre TA, Cheah CY, Ujjani CS, et al. Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma. J Clin Oncol. 2023;41:3988\u201397.","journal-title":"J Clin Oncol"},{"key":"3032_CR8","doi-asserted-by":"crossref","unstructured":"Furqan F, Palen K, Johnson B, Kearl T, Hematti P, Longo WL, et al. Combination of pirtobrutinib and lentiviral transduced bispecific anti-CD20\/CD19 (LV20. 19) CAR T-cell therapy to improve outcomes in patients with relapsed\/refractory lymphoma. Am Soc Clin Oncol. 2024;42.","DOI":"10.1200\/JCO.2024.42.16_suppl.7043"},{"key":"3032_CR9","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1158\/2159-8290.CD-22-0964","volume":"13","author":"SM Larson","year":"2023","unstructured":"Larson SM, Walthers CM, Ji B, Ghafouri SN, Naparstek J, Trent J, et al. CD19\/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive\/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma. Cancer Discov. 2023;13:580\u201397.","journal-title":"Cancer Discov"},{"key":"3032_CR10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ymthe.2022.09.003","volume":"31","author":"N Watanabe","year":"2023","unstructured":"Watanabe N, Mo F, Zheng R, Ma R, Bray VC, van Leeuwen DG, et al. Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies. Mol Ther. 2023;31:24\u201334.","journal-title":"Mol Ther"},{"key":"3032_CR11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41590-020-00818-9","volume":"22","author":"V Verma","year":"2021","unstructured":"Verma V, Jafarzadeh N, Boi S, Kundu S, Jiang Z, Fan Y, et al. MEK inhibition reprograms CD8(+) T lymphocytes into memory stem cells with potent antitumor effects. Nat Immunol. 2021;22:53\u201366.","journal-title":"Nat Immunol"},{"key":"3032_CR12","doi-asserted-by":"crossref","unstructured":"Mestermann K, Giavridis T, Weber J, Rydzek J, Frenz S, Nerreter T, et al. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells. Sci Transl Med. 2019;11.","DOI":"10.1126\/scitranslmed.aau5907"},{"key":"3032_CR13","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41590-024-02042-1","volume":"26","author":"F Song","year":"2025","unstructured":"Song F, Tsahouridis O, Stucchi S, Walhart T, Mendell S, Hardy PB, et al. A multi-kinase inhibitor screen identifies inhibitors preserving stem-cell-like chimeric antigen receptor T cells. Nat Immunol. 2025;26:279\u201393.","journal-title":"Nat Immunol"},{"key":"3032_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12494-x","volume":"10","author":"R Caeser","year":"2019","unstructured":"Caeser R, Di Re M, Krupka JA, Gao J, Lara-Chica M, Dias JML, et al. Genetic modification of primary human B cells to model high-grade lymphoma. Nat Commun. 2019;10:4543.","journal-title":"Nat Commun"},{"key":"3032_CR15","doi-asserted-by":"publisher","first-page":"4212","DOI":"10.1158\/1078-0432.CCR-16-2703","volume":"23","author":"L Zhang","year":"2017","unstructured":"Zhang L, Nomie K, Zhang H, Bell T, Pham L, Kadri S, et al. B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy. Clin Cancer Res. 2017;23:4212\u201323.","journal-title":"Clin Cancer Res"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03032-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03032-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03032-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T07:07:19Z","timestamp":1787641639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03032-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3032"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03032-y","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"17 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MW is consultant to AbbVie, Acerta Pharma, AstraZeneca, BeiGene, BioInvent, Deciphera, InnoCare, Janssen, Kite Pharma, Leukemia & Lymphoma Society, Lilly, Merck, Milken Institute, Oncternal, Parexel, Pepromene Bio, Pharmacyclics, and VelosBio, and he has received research support from Acerta Pharma, AstraZeneca, BeiGene, BioInvent, Celgene, Genmab, Genentech, Innocare, Janssen, Juno Therapeutics, Kite Pharma, Lilly, Loxo Oncology, Molecular Templates, Oncternal, Pharmacyclics, VelosBio, Vincerx. M.W. also received a speaker honorarium from AbbVie, Acerta Pharma, AstraZeneca, BeiGene, BioInvent, Dava Oncology, Eastern Virginia Medical School, IDEOlogy Health, Janssen, Kite Pharma, Leukemia & Lymphoma Society, LLC TS Oncology, Medscape, Meeting Minds Experts, MJH Life Sciences, Merck, Moffit Cancer Center, Oncology Specialty Group, OncLive, Pharmacyclics, Physicians Education Resources (PER), Practice Point Communications (PPC), and Studio ER Congressi. The remaining authors have no conflicts of interest to declare.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Written informed consent was obtained from all participants in the original studies from which the data and patient-derived xenograft (PDX) models were generated, in accordance with Institutional Review Board-approved protocols. The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board at The University of Texas MD Anderson Cancer Center.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}